Gruppo Italiano Malattie EMatologiche dell'Adulto

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Conditions: Idiopathic Thrombocytopenic Purpura

Interventions: Other: Observation

First Posted Date: 2018-03-14

Last Posted Date: 2022-07-20

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 861

Registration Number: NCT03465020

Locations: 🇮🇹
Sc Ematologia E Centro Trapianti Midollo Osseo, Parma, SC, Italy
🇮🇹
Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
🇮🇹
Aou Federico Ii - Napoli - Uoc Ematologia, Napoli, Italy

and more 23 locations

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2018-03-06

Last Posted Date: 2023-11-24

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 77

Registration Number: NCT03455517

Locations: 🇮🇹
Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo, Perugia, Italy
🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica, Roma, Italy
🇮🇹
Università degli Studi di Roma "Sapienza", Roma, Italy

and more 28 locations

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax

First Posted Date: 2018-03-06

Last Posted Date: 2024-04-10

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 124

Registration Number: NCT03455504

Locations: 🇮🇹
Aou Senese - Uoc Ematologia E Trapianti, Siena, Italy
🇮🇹
Spedali Civili - Azienda Ospedaliera U.O. Ematologia, Brescia, Italy
🇮🇹
Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia, Pagani, Italy

and more 19 locations

Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Other: Observation of CNS involvement

First Posted Date: 2018-01-25

Last Posted Date: 2022-10-26

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 21

Registration Number: NCT03410407

Locations: 🇮🇹
Asl Di Piacenza, Ospedale "Guglielmo Da Saliceto" - Ematologia E Centro Trapianti, Piacenza, Italy
🇮🇹
Aou Maggiore Della Carita' Di Novara - Scdu Ematologia, Novara, Italy
🇮🇹
Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia, Alessandria, Italy

and more 11 locations

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

Phase 2

Conditions: Philadelphia Chromosome-Negative B-Cell Precursor
Acute Lymphoid Leukemia

Interventions: Drug: Chemotherapy + Blinatumomab

First Posted Date: 2017-12-08

Last Posted Date: 2022-01-04

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 149

Registration Number: NCT03367299

Locations: 🇮🇹
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy
🇮🇹
Azienda Ospedaliera - Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
UOC di Ematologia - Istituto Tumori - Giovanni Paolo II, Bari, Italy

and more 59 locations

Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Dasatinib and blinatumomab

First Posted Date: 2017-10-24

Last Posted Date: 2022-10-12

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 60

Registration Number: NCT03318770

Locations: 🇮🇹
Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia, Bergamo, Italy
🇮🇹
Aou Careggi - Firenze - Sod Ematologia, Firenze, Italy
🇮🇹
Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia, Orbassano, Italy

and more 14 locations

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

Conditions: Multiple Myeloma

Interventions: Other: Quality of life questionnaires

First Posted Date: 2017-06-16

Last Posted Date: 2022-06-29

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 520

Registration Number: NCT03190525

Locations: 🇮🇹
Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy
🇮🇹
S. Orsola Malpighi, Bologna, Italy
🇮🇹
Divisione di Ematologia Ospedale A. Perrino, Brindisi, Italy

and more 31 locations

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

Conditions: Acute Promyelocytic Leukemia

Interventions: Other: QoL questionnaires

First Posted Date: 2017-03-30

Last Posted Date: 2021-02-08

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 161

Registration Number: NCT03096496

Locations: 🇮🇹
Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia, Brescia, Italy
🇮🇹
UOC Ematologia e Terapia Cellulare - Ospedale C. e G. Mazzoni di Ascoli Piceno, Ascoli Piceno, Italy
🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia - Padiglione Marcora 2do piano, Milano, Italy

and more 13 locations

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2017-03-09

Last Posted Date: 2019-03-21

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 337

Registration Number: NCT03075969

Locations: 🇦🇹
Innsbruck Medical University, Innsbruck, Austria
🇺🇸
Winship Cancer Institute of Emory University, Emory, Georgia, United States
🇨🇳
Guangdong Medical University, Guangdong, China

and more 29 locations

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Completed

Conditions: AML, Adult

Interventions: Genetic: IDH mutation test performed at diagnosis or relapse until January 31st, 2019.

First Posted Date: 2016-12-08

Last Posted Date: 2022-01-04

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 388

Registration Number: NCT02986620

Locations: 🇮🇹
AOU Policlinico G. Martino, Messina, Italy
🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano, Milano, Italy
🇮🇹
Università degli Studi di Padova - Ematologia ed Immunologia Clinica, Padova, Italy

and more 21 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy